Includes Full Exercise of Underwriters’ Overallotment Option Includes Full Exercise of Underwriters’ Overallotment Option
Read the rest here:
BioVie Announces Closing of Public Offering of Common Stock
Live webinar on October 1st to feature presentations by 3 KOLs in dermatology Live webinar on October 1st to feature presentations by 3 KOLs in dermatology
Go here to read the rest:
VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™
FALLBROOK, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- CannAssist International Corporation (OTCQB: CNSC) (“Cannassist” or the “Company”) is pleased to announce the Company is now a new Publicly Traded Company on the OTC Markets Platform - OTCQB Markets Tier. The OTCQB requires a company to be fully reporting under SEC rules and guidelines as a means of accomplishing full transparency for Investors.
BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000.
Read the original post:
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies
BUENA, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible Senior Notes due 2023 (the “New 2023 Notes”) in exchange for approximately $57.9 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 4.75% Convertible Senior Notes due May 2023 (the “Series A Convertible Notes”), which gives effect to a 52.5% discount on the principal amount of Series A Convertible Notes exchanged. The Company also issued approximately $0.4 million aggregate principal amount of New 2023 Notes in exchange for approximately $0.5 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes due 2023 (the “Series B Convertible Notes”), which gives effect to a 31% discount on the principal amount of Series B Convertible Notes exchanged.
More here:
Teligent Announces Completion of Series D Convertible Note Exchange
--Final 12-Month Results from Phase II Trial to be Presented on October 1--LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).
Here is the original post:
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society...
BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.
Original post:
Caladrius Biosciences to Present at the BIO Investor Forum Digital
Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research
Continued here:
CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.
STAMFORD, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Originally posted here:
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock